---
title: "Replimune's stock price has doubled after the U.S. FDA accepted its supplemental application for pot"
description: "Replimune's stock price has doubled after the U.S. FDA accepted its supplemental application for potential approval of its skin cancer drug, with the latest increase reaching 106.2%"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261903770.md"
published_at: "2025-10-20T13:41:23.000Z"
---

# Replimune's stock price has doubled after the U.S. FDA accepted its supplemental application for pot

> Replimune's stock price has doubled after the U.S. FDA accepted its supplemental application for potential approval of its skin cancer drug, with the latest increase reaching 106.2%

Replimune's stock price doubled after the U.S. FDA accepted its supplemental application for potential approval of its skin cancer drug, with the latest increase reaching 106.2%

### Related Stocks

- [REPL.US - Replimune](https://longbridge.com/en/quote/REPL.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Forget AI stocks: This pharma giant is using AI to dominate drug discovery | And there's more than one way to monetize this technology. | [Link](https://longbridge.com/en/news/276017486.md) |
| Nuclera and leadXpro Partner to Accelerate Structure-Based Drug Design for Complex Membrane Proteins | Nuclera and leadXpro have announced a partnership to enhance structure-based drug design for complex membrane proteins.  | [Link](https://longbridge.com/en/news/276109364.md) |
| 06:07 ETMolecule Found to Drive Skin Cancer Growth and Evade Immune Detection | A study led by NYU Langone Health reveals that the transcription factor HOXD13 drives skin cancer growth and helps tumor | [Link](https://longbridge.com/en/news/275593928.md) |
| IDT Australia Reports Operational Improvements with New Leadership Team and Realignment Strategy | IDT Australia reported operational improvements under a new leadership team and realignment strategy, with a 20.3% incre | [Link](https://longbridge.com/en/news/276194130.md) |
| Roche Says Its Blood Cancer Drug Shows Positive Results in Trial | Roche announced that its blood cancer drug Gazyva/Gazyvaro has shown positive results in a late-stage trial for patients | [Link](https://longbridge.com/en/news/276037735.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.